Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Ajmaline

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44364   clinical trials with a EudraCT protocol, of which   7388   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    3 result(s) found for: Ajmaline. Displaying page 1 of 1.
    EudraCT Number: 2018-000752-18 Sponsor Protocol Number: 17-924 Start Date*: 2019-02-19
    Sponsor Name:UMC Utrecht
    Full Title: Ajmaline provocation in asymptomatic PLN and PKP2 mutation carriers for early detection of Arrhythmogenic Cardiomyopathy
    Medical condition: Arrhythmogenic cardiomyopathie due to PLN or PKP2 mutations, asymptomatic family members who are carriers of PLN or PKp2 mutations, patients without structural heart disease who are referred for aj...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004277-41 Sponsor Protocol Number: 16.0012 Start Date*: 2017-01-18
    Sponsor Name:St George's University of London
    Full Title: An observational study into the variety of electrocardiographic responses to an ajmaline Provocation in healthy subjects. What are the genetic and structural variations dictating this response ?
    Medical condition: Study in the healthy population. This is a study of a test used in the diagnosis of the condition, Brugada Syndrome.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003109 Arrest cardiac LLT
    20.0 10007541 - Cardiac disorders 10003119 Arrhythmia PT
    20.0 10007541 - Cardiac disorders 10059027 Brugada syndrome PT
    20.1 100000004867 10042436 Sudden death unexplained LLT
    21.0 100000004848 10069779 Brugada-type ECG LLT
    20.0 100000004848 10008396 Change in ECG LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000584-25 Sponsor Protocol Number: FLAM01 Start Date*: 2012-03-29
    Sponsor Name:UZBrussel
    Full Title: Propofol and etomidate. Are they also safe for patients with Brugada-Syndrome?
    Medical condition: Patients suspected to have Brugada Syndrome
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Oct 30 08:02:40 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA